Home › Funds › ARMISTICE CAPITAL, LLC › MLYS

ARMISTICE CAPITAL, LLC position in MLYS

MINERALYS THERAPEUTICS INC · Health Care

ARMISTICE CAPITAL, LLC reported holding 1,600,000 shares of MLYS (MINERALYS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$40.2M, representing 0.55% of its reported portfolio and ranking #21 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed MLYS holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)1.60M sh
Reported value held$40.21M
Portfolio Weight0.55%
First reportedQ2 2025
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's MLYS position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in MLYS in Q2 2025 at 178,000 shares (US$2.4M). The position peaked in Q3 2026 at 1,600,000 shares, worth US$40.2M. Across 6 filings, ARMISTICE CAPITAL, LLC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,600,000 shares valued at US$40.2M — an increase of 560,000 shares quarter over quarter.. Notable position changes include a 185% increase in Q3 2025 (shares fell 4% over the following quarter), a 74% increase in Q1 2026 (shares were roughly flat over the following quarter), a 54% increase in Q3 2026 (shares fell 39% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 178.00K $2.41M New
Q3 2025 507.65K $19.25M Add
Q4 2025 676.03K $24.53M Add
Q1 2026 1.18M $31.86M Add
Q2 2026 1.04M $28.06M Reduce
Q3 2026 1.60M $40.21M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MLYS and 13F data

MLYS (MINERALYS THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MLYS

All MLYS fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held MLYS?

ARMISTICE CAPITAL, LLC has disclosed MLYS holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is ARMISTICE CAPITAL, LLC's current position in MLYS?

As of Q3 2026, ARMISTICE CAPITAL, LLC holds 1.60M shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $40.21M, representing 0.55% of its reported portfolio and ranking #21.

Has ARMISTICE CAPITAL, LLC been buying or selling MLYS?

In the latest 13F filing (Q3 2026), ARMISTICE CAPITAL, LLC increased its position in MLYS. The position peaked in Q3 2026 at 1.60M shares.

Which other funds hold MLYS?

Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.